Biogen Inc (BIIB) USD (CDI)

Sell:$125.00Buy:$125.06$3.89 (3.02%)

NASDAQ:0.05%
Market closed | Prices delayed by at least 15 minutes
Sell:$125.00
Buy:$125.06
Change:$3.89 (3.02%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$125.00
Buy:$125.06
Change:$3.89 (3.02%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Key people

Christopher A. Viehbacher
President, Chief Executive Officer, Director
Robin C. Kramer
Chief Financial Officer, Executive Vice President
Ginger Gregory
Chief Human Resources Officer, Executive Vice President
Susan H. Alexander
Executive Vice President, Chief Legal Officer
Jane Grogan
Executive Vice President, Head of Research
Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Adam James Keeney
Executive Vice President, Head of Corporate Development
Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Priya Singhal
Executive Vice President, Head of Development
Sean Godbout
Chief Accounting Officer, Vice President, Global Corporate Controller, Principal Accounting Officer
Caroline D. Dorsa
Independent Chairman of the Board
Maria C. Freire
Independent Director
William A. Hawkins
Independent Director
Susan Langer
Independent Director
Jesus B. Mantas
Independent Director
Click to see more

Key facts

  • EPIC
    BIIB
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US09062X1037
  • Market cap
    $18.82bn
  • Employees
    7,605
  • Shares in issue
    170.33m
  • Exchange
    NASDAQ
  • Index
    S&P 500, NASDAQ 100 Index, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.